Celyad’s CAR T-cell Therapy Shows Promise in 2 Patients with Advanced Colorectal Cancer

Celyad’s CAR T-cell Therapy Shows Promise in 2 Patients with Advanced Colorectal Cancer
New data from the Phase 1 THINK clinical trial (NCT03018405) show that two metastatic colorectal cancer (mCRC) patients whose disease progressed following at least two prior therapies had stabilized the disease at a three-month follow-up after receiving the lowest dose level of Celyad’s NKR-2 CAR T-cell therapy. The third person included in the dose cohort, a pancreatic cancer patient, had disease progression at three months, but the findings suggest that this CAR T-cell therapy induces better results than standard of care, under which the time to disease progression is between 1.9 and 3.2 months. “We are pleased to have observed these encouraging preliminary results in such a late stage population,” Christian Homsy, Celyad’s CEO, said in a press release. “Despite being dosed only at a tenth of the expected efficacious dose based on animal experiments, the results show a stabilization of the disease. We look forward to the next stages of the trial.” The open-label THINK trial, conducted in the U.S. and Europe, is a dose escalation Phase 1 study to assess the safety and clinical activity of three administrations of NKR-2 cells across seven cancer types. The study is designed to include patients with five types of solid tumors (colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers) and two types of blood cancers (acute myeloid leukemia and multiple myeloma). Celyad’s NKR-2 CAR T-cell therapy is a personalized therapy that isolates a patient’s own T-cells, a type of white blood cell, and adds a protein called NKG2D to the cells. NKG2D helps T-cells recognize and kill tumor cells. Once they are “armed” with NKG2D, the T-cells are returned to the patient’s circulation. Pre-clinical studies of NKR-2 CAR T-cell
Subscribe or to access all post and page content.